Hydroxyurea Reduced Mortality for Children With Sickle Cell Anemia

A 10-year study in sub-Saharan Africa revealed that a higher dose of the oral medication Hydroxyurea improved survival and growth outcomes in children with sickle cell anemia.

RT’s Three Key Takeaways:

1. Mortality Reduction: Children with sickle cell anemia in sub-Saharan Africa saw an 80% decrease in mortality when treated with hydroxyurea compared to those not on the treatment.
2. Clinical Outcomes: A maximum tolerated dose of the medication led to fewer hospitalizations, blood transfusions, and severe pain episodes.
3. Growth and Development: Long-term use of hydroxyurea resulted in significant improvements in height and weight, suggesting better nutrition outcomes for pediatric patients.